US EditionAbbVie Pays $700M for Drug Engineered to Overcome Resistance in Multiple Myeloma
NORTH AMERICA, EUROPE, JAPAN, AND CHINA, JUL 10 – AbbVie paid $700 million upfront for ISB 2001, a trispecific antibody with a 79% response rate in early trials for multiple myeloma, aiming to accelerate development globally.
- On Thursday, AbbVie committed an initial payment of $700 million to secure exclusive rights to ISB 2001, a trispecific antibody created by Ichnos Glenmark Innovation .
- This deal follows IGI's formation in 2024 from Ichnos Sciences and Glenmark Pharmaceuticals and builds on prior multispecific antibody advances in multiple myeloma treatment.
- ISB 2001 targets CD38, BCMA, and CD3 within one molecule, showed a 79% overall response rate in heavily pretreated patients, and was generally well tolerated in Phase 1 trials.
- AbbVie's chief scientific officer Roopal Thakkar described multispecific antibodies as an emerging area in immuno-oncology that holds promise for achieving stronger and longer-lasting therapeutic effects by targeting several molecules at once.
- The deal could total $1.925 billion with milestones and royalties, positioning ISB 2001 for development in major markets while Glenmark retains commercialization rights in emerging regions.
16 Articles
16 Articles
AbbVie Pays $700M for Drug Engineered to Overcome Resistance in Multiple Myeloma
AbbVie has acquired rights to a multispecific antibody that IGI Therapeutics designed to bind to three targets to treat multiple myeloma. Early Phase 1 results showed encouraging responses in a heavily pretreated patient population and a favorable safety profile.
Glenmark Unit to License Blood Cancer Drug to Abbvie for $700 Million Upfront
A unit of Glenmark Pharmaceuticals Ltd., Ichnos Glenmark Innovation, has entered into a pact with AbbVie Inc. to license its under-development multiple myeloma drug for an upfront payment of $700 million.
AbbVie announces global licensing deal with IGI for new cancer therapy
AbbVie and Ichnos Glenmark Innovation (IGI) have announced an exclusive licensing agreement for ISB 2001, a trispecific antibody currently in Phase 1 clinical trials for relapsed/refractory multiple myeloma. This partnership grants AbbVie the rights to develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China."Multispecifics including trispecific antibodies represent a new frontier in immuno-oncology…
Coverage Details
Bias Distribution
- 57% of the sources are Center
To view factuality data please Upgrade to Premium
